Shanxi Taxus Pharma To Buy Majority Stake In Unnamed U.S. Firm
This article was originally published in PharmAsia News
Executive Summary
China's Shanxi Taxus Pharmaceutical said it plans to buy a majority stake in a regenerative-medicine company in California for $5 million cash, but would not disclose the company's name.